Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Akeso, Inc. Stock

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:12 2024-06-17 am EDT 		5-day change 1st Jan Change
40.8 HKD +2.38% Intraday chart for Akeso, Inc. +0.37% -12.07%
Jun. 04 Akeso Expands Territory of License Agreement for Lung Cancer Drug MT
Jun. 03 Summit Therapeutics Inc. Expands License Territories for Ivonescimab CI

Financials

Sales 2024 * 2.63B 362M 2.83B Sales 2025 * 4.15B 572M 4.46B Capitalization 32.05B 4.42B 34.5B
Net income 2024 * -433M -59.68M -466M Net income 2025 * 220M 30.32M 237M EV / Sales 2024 * 12.9 x
Net Debt 2024 * 1.71B 236M 1.84B Net Debt 2025 * 420M 57.95M 453M EV / Sales 2025 * 7.83 x
P/E ratio 2024 *
-70.5 x
P/E ratio 2025 *
140 x
Employees 2,778
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.33%
More Fundamentals * Assessed data

Chart Akeso, Inc.

Dynamic Chart

Latest news about Akeso, Inc.

Akeso Expands Territory of License Agreement for Lung Cancer Drug MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15% MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF) CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20% MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI
Akeso to Raise Over HK$1 Billion Via Share Sale MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5% MT
More news

Analyst Recommendations on Akeso, Inc.

Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy MT
More recommendations

Press releases Akeso, Inc.

Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 AQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024 AQ
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 AQ
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap PR
More press releases

Quotes and Performance

1 day+2.38%
1 week+5.43%
Current month-7.27%
1 month-16.22%
3 months-21.31%
6 months-9.13%
Current year-12.07%
More quotes

Highs and lows

1 week
38.25
Extreme 38.25
40.90
1 month
26.45
Extreme 26.45
60.00
Current year
26.45
Extreme 26.45
60.00
1 year
26.45
Extreme 26.45
60.00
3 years
11.50
Extreme 11.5
66.00
5 years
11.50
Extreme 11.5
69.90
10 years
11.50
Extreme 11.5
69.90
More quotes

Managers and Directors - Akeso, Inc.

Managers TitleAgeSince
Baiyong Li FOU
 Founder 56 12-03-18
Peng Zhang FOU
 Founder 48 12-03-18
Michelle Xia CEO
 Chief Executive Officer 57 12-03-18
Members of the board TitleAgeSince
Bo Tan BRD
 Director/Board Member 51 20-03-31
Zhongmin Wang FOU
 Founder 55 12-03-18
Yan Xu BRD
 Director/Board Member 61 20-03-31
More insiders

ETFs positioned on Akeso, Inc.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.57% 4 M€ -27.92%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.44% 2 M€ -14.14%
More ETFs positioned on Akeso, Inc.

Quotes

Date Price Change Volume
24-06-17 40.8 +2.38% 5 541 554
24-06-14 39.85 -0.62% 3,866,636
24-06-13 40.1 +2.17% 4,339,942
24-06-12 39.25 +1.42% 6,101,115
24-06-11 38.7 -4.80% 7,568,922

Delayed Quote Hong Kong S.E., June 17, 2024 at 04:08 am EDT

More quotes

Company Profile

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Sector
Biotechnology & Medical Research
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
37.01 CNY
Average target price
54.78 CNY
Spread / Average Target
+48.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKESO, INC. Stock Akeso, Inc.
-12.07% 4.42B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
ARGENX SE Stock argenx SE
+3.87% 22.94B
BIONTECH SE Stock BioNTech SE
-12.75% 22.22B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
GENMAB A/S Stock Genmab A/S
-16.01% 16.88B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock